Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:49:43.160Z.
Calculation as of: 2026-10-06T19:49:43.160Z.
Quote observation: 2026-10-06T19:45:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8daa83f2db5fafa0746e2d75675d68491b64c400a2027f88c30977eae97731f
PEG RATIO
N/A
Market Cap
$348.81M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.82M
PEG Ratio
N/A
TTM Avg
47.60
3Y Avg
47.60
5Y Avg
23.01
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $346.88M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.82M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $348.81M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $349.74M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.82M | N/A | 47.60 | 47.60 | 23.01 |
| Viemed Healthcare, Inc. (VMD)vs › | $354.03M | N/A | 38.27 | 19.74 | 13.07 |
| Ocugen, Inc. (OCGN)vs › | $353.49M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.88M | N/A | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $359.28M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.82M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
